News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bio-Rad Laboratories, Inc. (BIO) Release: Researchers Use the ProteOn™ XPR36 System to Study the Mechanisms Underlying Cancer, Alzheimer's Disease, and Other Conditions


9/25/2012 11:32:43 AM

Hercules, CA — September 25, 2012 — Bio-Rad Laboratories, Inc. announces the extension of the Protein Function Division’s ongoing ProteOn webinar series, which showcases the latest cancer and disease research utilizing the ProteOn XPR36 protein interaction array system, an instrument that uses surface plasmon resonance (SPR) to generate rich, label-free kinetic binding data. Previously presented topics include the use of SPR for the identification and characterization of phosphoinositide signaling lipids that have been linked to cancer and in studies aimed at understanding protein misfolding, aggregation, and tissue deposition associated with neurodegenerative conditions such as Alzheimer’s disease.

“The webinars introduced the latest applications of SPR technology for drug discovery workflows and provided valuable updates on the instrument’s software and hardware,” said Dr Ralf J. Hosse, Antibody Engineering Group Leader at Roche Glycart in Switzerland.

Cancer and Alzheimer’s Disease Applications

In a July 2012 webinar, Dr Lily Sommer of the Paterson Institute for Cancer Research in Manchester, U.K., described the identification and characterization of novel phosphoinositide-binding proteins using the ProteOn XPR36 system. Phosphoinositides are signaling lipids whose misregulation has been linked to cancer. The studies were undertaken using Bio-Rad’s ProteOn liposome capturing kit, which uses DNA hybridization to selectively capture liposomes to detect phosphoinositide-protein interactions.

Marco Gobbi of the Mario Negri Institute in Milan, Italy hosted a webinar session titled “Novel Applications of SPR to Study Amyloidogenic Peptides and Proteins.” He discussed novel SPR screening applications for both mutation analysis and investigating the effects anti-amyloidogenic drug candidates. The results of this work were published in the Journal of Biological Chemistry in June 2012.

An increasing number of diseases are now being associated with misfolding, aggregation, and tissue deposition of specific proteins, such as in Alzheimer’s disease. Soluble oligomers of the amyloid-ß (Aß) peptide play a key role in the pathogenesis of Alzheimer’s disease, but their elusive nature makes detection challenging. Gobbi and his team demonstrated that SPR measurements can be particularly useful for the kinetic analysis of the elongation of amyloid fibrils and the detection of soluble oligomeric species, which cannot be achieved by other techniques.

Best Practices in SPR

The webinar series kicked off with a session that focused on guidelines developed by Professor Gideon Schreiber of the Weizmann Institute of Science in Israel advising researchers on how to best perform label-free interaction analysis. Dr Schreiber is well known in the label-free field and has hosted and chaired many conferences on this topic.

Drug Discovery and Development Applications

Dr Dalia Shezifi, manager of the Bio-Rad Haifa Applications Team in Israel, focused on label-free analysis of small molecules and peptides binding to liposomes. Her work demonstrated how the ProteOn liposome capturing kits have been used to address important issues in drug development, such as the binding of small molecule drugs to liposomes when estimating the intestinal absorptivity of new drugs.

To conclude the series, Gary Ross, a Bio-Rad field application specialist, described how the ProteOn system was used to perform antibody quantification and full protein kinetic analysis in a single 45-minute experiment. This application is an important advance for researchers involved in antibody screening, as it provides rich data in a single experiment on a single platform, saving bench time.

“The presentations were a good way to inspire new ideas and assays that may be performed in the future,” said Johan Nilvebrant, a PhD student at the KTH Royal Institute of Technology in Sweden.

New Season, New Series

Bio-Rad’s next SPR webinar series will take place this fall, kicking off on Sept. 25 with a presentation by Dr Carlotta Chiappa, a research scientist at the DiaSorin Research Center in Geranzano, Italy, on antibody screening for the development of a diagnostic test for Clostridium difficile. In October, Dr Jonathan Popplewell, a Bio-Rad application scientist, will present a webinar focusing on best practices for SPR data processing and downstream analysis. Dr Lisa Scalfone, a postdoctoral researcher at the Stanford University School of Medicine, will talk about how the ProteOn XPR36 system was used in a novel workflow to develop antibodies against the influenza virus. The last speaker in the fall series, Dr Ladislav Bumba, a postdoctoral researcher at the Institute of Microbiology in Prague, Czech Republic, will discuss the analysis of the interactions of bacterial toxins with target cell molecules in bacterial pathogenesis.

Please visit http://bit.ly/PO_Webinar_Registration to register.

All the webinars from this series can be viewed at http://bit.ly/ProteOn_YouTube.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, and major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Laura Moriarty

Bio-Rad Laboratories, Inc.

510-741-5613

Laura_Moriarty@bio-rad.com

Ken Li

Chempetitive Group

312-997-2436 x 112

kli@chempetitive.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES